This antibody is first purified by protein G affinity chromatography. Then, the antibody fraction is peptide affinity purified. The antibody is eluted with high and low pH buffers and neutralized immediately, followed by dialysis against PBS.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
IHC-P: 1/10 - 1/50.
WB: 1/50 - 1/100. Detects bands of approximately 65 and 130 kDa (predicted molecular weight: 65 kDa).
Not yet tested in other applications.
Optimal dilutions/concentrations should be determined by the end user.
Tyrosine protein phosphatase which functions as a dosage-dependent inducer of mitotic progression. Required for G2/M phases of the cell cycle progression and abscission during cytokinesis in a ECT2-dependent manner. Directly dephosphorylates CDK1 and stimulates its kinase activity. The three isoforms seem to have a different level of activity.
Belongs to the MPI phosphatase family. Contains 1 rhodanese domain.
Phosphorylated by BRSK1 in vitro. Phosphorylated by CHEK1, which inhibits the activity of this protein. Phosphorylation at Ser-353 by AURKA might locally participate in the control of the onset of mitosis. Phosphorylation by MELK at Ser-169 promotes localization to the centrosome and the spindle poles during mitosis. Phosphorylation at Ser-323 and Ser-375 by MAPK14 is required for binding to 14-3-3 proteins.
Cytoplasm, cytoskeleton, microtubule organizing center, centrosome. Cytoplasm, cytoskeleton, spindle pole.
Formalin fixed, paraffin embedded human breast carcinoma tissue reacted with a70927 at a 1/10 dilution, by Immunohistochemistry. ab70927 was peroxidase conjugated to the secondary antibody, followed by DAB staining.
Xie D et al. miR-152 inhibits proliferation of human endometrial cancer cells via inducing G2/M phase arrest by suppressing CDC25B expression. Biomed Pharmacother99:299-305 (2018).
Read more (PubMed: 29353204) »
Yu XY et al. MicroRNA-141 is downregulated in human renal cell carcinoma and regulates cell survival by targeting CDC25B. Onco Targets Ther6:349-54 (2013).
Read more (PubMed: 23596351) »